Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neuromuscular Reversal Agents for Neurological Assessment After Intubation
NCT05993390Recruiting
- Sponsor
- Seoul National University Hospital
- Start
- Jan 2024
- Primary completion
- Aug 2027
- Modality
- Biodegradable Polymers, Small Molecules
- Countries
- 1
01
Overview
Randomised, double-blind trial of Sugammadex and neostigmine in neuromuscular blockade (NMB) (3 arms), sponsored by Seoul National University Hospital. Primary endpoint: Time from administration of neuromuscular blocker to the first available neurologic assessment up to 48 hours. Started Jan 2024; status: recruiting.
02
Drugs
Sugammadexneostigmine
03
Conditions
neuromuscular blockade (NMB)
Beyond the preview
Go deeper on NCT05993390.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05993390.